Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study
-
Published:2024-06
Issue:
Volume:47
Page:101096
-
ISSN:2666-6065
-
Container-title:The Lancet Regional Health - Western Pacific
-
language:en
-
Short-container-title:The Lancet Regional Health - Western Pacific
Author:
Xu Min,
Shu Jinhui,
Qian Shenxian,
Guo Jingming,
Gong Yuping,
Huang Ruibin,
Wang Shuye,
Zhou Zeping,
Yuan Guolin,
Huang Meijuan,
Lin Li-E,
Lou Shifeng,
Song Yanping,
Liu Qingchi,
Zhou Hu,
Mei HengORCID,
Hu YuORCID